Viral MicroRNAs in Herpes Simplex Virus 1 Pathobiology
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Simplexvirus humanalpha1 infects millions of people globally, manifesting as vesiculo-ulcerative lesions of the oral or genital mucosa. After primary infection, the virus establishes latency in the peripheral neurons and reactivates sporadically in response to various environmental and genetic factors. A unique feature of herpesviruses is their ability to encode tiny noncoding RNAs called microRNA, (miRNAs). Simplexvirus humanalpha1 encodes eighteen miRNA precursors that generate twenty-seven different mature miRNA sequences. Unique Simplexvirus humanalpha1 miRNAs repertoire is expressed in lytic and latent stages and exhibits expressional disparity in various cell types and model systems suggesting their key pathological functions. This review will focus on elucidating the mechanisms underlying HSV-1 encoded viral miRNAs regulation of host-virus interaction. Numerous studies have demonstrated sequence-specific targeting of both viral and host transcripts by Simplexvirus humanalpha1 miRNAs. While these noncoding RNAs predominantly target viral genes involved in viral life cycle switch, they regulate host genes involved in antiviral immunity, thereby facilitating viral evasion and lifelong viral persistence inside the host. Expression of Simplexvirus humanalpha1 miRNAs has been associated with disease progression and resolution. Systemic circulation and stability of viral miRNAs compared to viral mRNAs can be harnessed to utilize their potential as diagnostic and prognostic markers. Moreover, functional inhibition of these enigmatic molecules may allow us to devise strategies that have therapeutic significance to contain Simplexvirus humanalpha1 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - (2024) vom: 12. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Naqvi, Raza Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral therapeutics |
|---|
| Anmerkungen: |
Date Revised 13.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113816128286469240129100313 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368379051 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368379051 | ||
| 003 | DE-627 | ||
| 005 | 20240213233133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113816128286469240129100313 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1291.xml |
| 035 | |a (DE-627)NLM368379051 | ||
| 035 | |a (NLM)38347772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Naqvi, Raza Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Viral MicroRNAs in Herpes Simplex Virus 1 Pathobiology |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Simplexvirus humanalpha1 infects millions of people globally, manifesting as vesiculo-ulcerative lesions of the oral or genital mucosa. After primary infection, the virus establishes latency in the peripheral neurons and reactivates sporadically in response to various environmental and genetic factors. A unique feature of herpesviruses is their ability to encode tiny noncoding RNAs called microRNA, (miRNAs). Simplexvirus humanalpha1 encodes eighteen miRNA precursors that generate twenty-seven different mature miRNA sequences. Unique Simplexvirus humanalpha1 miRNAs repertoire is expressed in lytic and latent stages and exhibits expressional disparity in various cell types and model systems suggesting their key pathological functions. This review will focus on elucidating the mechanisms underlying HSV-1 encoded viral miRNAs regulation of host-virus interaction. Numerous studies have demonstrated sequence-specific targeting of both viral and host transcripts by Simplexvirus humanalpha1 miRNAs. While these noncoding RNAs predominantly target viral genes involved in viral life cycle switch, they regulate host genes involved in antiviral immunity, thereby facilitating viral evasion and lifelong viral persistence inside the host. Expression of Simplexvirus humanalpha1 miRNAs has been associated with disease progression and resolution. Systemic circulation and stability of viral miRNAs compared to viral mRNAs can be harnessed to utilize their potential as diagnostic and prognostic markers. Moreover, functional inhibition of these enigmatic molecules may allow us to devise strategies that have therapeutic significance to contain Simplexvirus humanalpha1 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Herpes Simplex Virus Type 1 | |
| 650 | 4 | |a antiviral therapeutics | |
| 650 | 4 | |a diagnostics markers | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a microRNAs | |
| 650 | 4 | |a viral persistence | |
| 700 | 1 | |a Valverde, Araceli |e verfasserin |4 aut | |
| 700 | 1 | |a Yadavalli, Tejabhiram |e verfasserin |4 aut | |
| 700 | 1 | |a Bobat, Fatima Ismail |e verfasserin |4 aut | |
| 700 | 1 | |a Capistrano, Kristelle J |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Naqvi, Afsar R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g (2024) vom: 12. Feb. |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113816128286469240129100313 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 02 | ||